Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 20/20 | 1.00 |
| ▸ | NCOR2 | Q9Y618 | 6/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.75 |
| ▸ | HTR1D | P28221 | 1/20 | 0.75 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.75 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.75 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.75 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.75 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20568909 | 1.00 | BCL6 (1.00) | BCL6NCOR2ADRB3HTR1DADORA1 | |
| Formic Acid SCHEMBL26982943 | 0.97 | BCL6 (0.94) | BCL6NCOR2ADRB3HTR1DADORA1 | |
| SCHEMBL23357506 | 0.92 | BCL6 (0.90) | BCL6NCOR2ADRB3HTR1DADORA1 | |
| SCHEMBL30745266 | 0.92 | BCL6 (0.90) | BCL6NCOR2ADRB3HTR1DADORA1 | |
| SCHEMBL20569708 | 0.91 | BCL6 (1.00) | BCL6NCOR2ADRB3HTR1DADORA1 | |
| SCHEMBL29960375 | 0.91 | BCL6 (1.00) | BCL6NCOR2ADRB3HTR1DADORA1 | |
| SCHEMBL29960188 | 0.91 | BCL6 (1.00) | BCL6NCOR2ADRB3HTR1DADORA1 | |
| SCHEMBL23357486 | 0.91 | BCL6 (1.00) | BCL6NCOR2ADRB3HTR1DADORA1 | |
| SCHEMBL23267548 | 0.91 | BCL6 (0.84) | BCL6NCOR2ADRB3HTR1DADORA1 | |
| SCHEMBL20569093 | 0.90 | BCL6 (1.00) | BCL6NCOR2ADRB3HTR1DADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630291-B9 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-05-29 | — | — | EP | claimed |
| CN-111163839-B | Benzimidazolone-derived BCL6 inhibitors | 癌症研究科技有限公司 | 2024-05-28 | — | — | CN | claimed |
| EP-3630291-B1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-01-10 | — | — | EP | claimed |
| EP-4061834-A1 | CHEMICALLY INDUCIBLE POLYPEPTIDE POLYMERIZATION | Dana-Farber Cancer Institute, Inc. (US) | 2022-09-28 | — | — | EP | claimed |
| CN-118561812-A | Benzimidazolone-derived BCL6 inhibitors | 癌症研究科技有限公司 | 2024-08-30 | — | — | CN | disclosed |
| EP-3630291-B9 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-05-29 | — | — | EP | disclosed |
| EP-4374858-A2 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | Cancer Research Technology Limited (GB) | 2024-05-29 | — | — | EP | disclosed |
| CN-111163839-B | Benzimidazolone-derived BCL6 inhibitors | 癌症研究科技有限公司 | 2024-05-28 | — | — | CN | disclosed |
| EP-3630291-B1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-01-10 | — | — | EP | disclosed |
| EP-4061834-A1 | CHEMICALLY INDUCIBLE POLYPEPTIDE POLYMERIZATION | Dana-Farber Cancer Institute, Inc. (US) | 2022-09-28 | — | — | EP | disclosed |